Frontlight ResearchEarly access
CompletedNo phase
Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
Key facts
- Who runs it
- University of Jazan
- Where
- Saudi Arabia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 664 people enrolled
- Started
- 1 Apr 2024
- Ended
- 1 Mar 2025
- Type of study
- Observational, 2 groups
- Record updated
- 30 March 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- All adult (≥ 18 year) patients who were admitted to ICU with sepsis syndromes (sepsis or septic shock), according to sepsis-3 definition
Who cannot take part
- Renal transplant or tumor
- Missing data
- Solitary kidney
- Established CKD
- Obstructive uropathy
- Renal artery stenosis
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.
The 2 groups in the trial
- SA-AKI Group
Patients diagnosed with sepsis syndromes (sepsis or septic shock) and AKI according to sepsis-3 definition and KDIGO criteria, respectively
- No AKI group
Patients diagnosed with sepsis syndromes (sepsis or septic shock) and AKI according to sepsis-3 definition
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Prior Sodium-Glucose Co-Transporter 2 Inhibitor Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
- Record updated
- 30 March 2025